(RTTNews) – Sanofi (SNYNF, SNY) announced Tuesday that the phase 3 trial of Kevzara (sarilumab) did not meet its number one endpoint and key secondary endpoint in COVID-19 patients outside the United States. .
The global phase 3 trial examining Kevzara given intravenously at a dose of 200 mg or 400 mg in critically ill patients hospitalized for COVID-19 failed to achieve its goals when Kevzara compared to placebo was added to the same hospital care of forever.
The randomized trial of 420 patients was conducted outdoors in the United States in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia and Spain.
In the trial, although not statistically significant, numerical trends were observed towards a minimize reduction in the length of hospital stay, as well as an acceleration in time to improve clinical outcomes. the first two weeks of treatment.
The company plans to send the detailed effects to a peer-reviewed publication by the end of this year.
At this time, Sanofi and Regeneron plan to conduct additional clinical studies on Kevzara in COVID-19.
Kevzara is recently approved in several countries to treat adults with moderate to severe active rheumatoid arthritis who have responded to or tolerated previous treatments.